Tratamentul cu β-eritropoietina generică (repretinar) şi calitatea vieţii pacienţilor dializaţi
Închide
Conţinutul numărului revistei
Articolul precedent
Articolul urmator
204 1
Ultima descărcare din IBN:
2023-03-01 13:37
SM ISO690:2012
TĂNASE, Adrian, CEPOIDA, Petru, GAIBU, Sergiu, VISTERNICEANU, Dorian, EVDOCHIMOVA, Larisa, POSTOLACHI, Lilia, CORNEA, Natalia. Tratamentul cu β-eritropoietina generică (repretinar) şi calitatea vieţii pacienţilor dializaţi. In: Arta Medica , 2011, nr. 2S(45), pp. 270-272. ISSN 1810-1852.
EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core
Arta Medica
Numărul 2S(45) / 2011 / ISSN 1810-1852 /ISSNe 1810-1879

Tratamentul cu β-eritropoietina generică (repretinar) şi calitatea vieţii pacienţilor dializaţi

Generic β-erhythropoietine (repretiner) therapy and the quality of life of the dialysed population


Pag. 270-272

Tănase Adrian, Cepoida Petru, Gaibu Sergiu, Visterniceanu Dorian, Evdochimova Larisa, Postolachi Lilia, Cornea Natalia
 
IMSP Spitalul Clinic Republican „Timofei Moșneaga”
 
 
Disponibil în IBN: 10 aprilie 2022


Rezumat

The prospective 3-months study of the influence of β-erythropoietine (Repretine®) administration on the quality of life in 20 dialyzed patients is described. Treatment dose was 6,000 UI/week. After the treatment hemoglobin levels increased significantly and 70% patients reported the quality of life amelioration. As the physical component of the quality of life index increased from 33,81±1,56 points (M±m) till 38,51±1,49 points (p<0,05) and the psychological component decreased insignificantly from 45,71±6,97 points till 44,77±6,5 points (p>0,05), than composed health index increased due to the amelioration of the physical stage of the patients, that positively correlated with increased hemoglobin values.